Questions that move a care discussion forward

Ask about the reason for care

• What problem are we assessing?
• What evidence applies to that problem?
• What would count as a worthwhile change for me?
• What other approaches belong in the discussion?

HIV means human immunodeficiency virus; lipodystrophy means body fat has changed its pattern.

As of September 2026, tesamorelin’s U.S. approval concerns excess belly fat for adults who have HIV and lipodystrophy.

Ask about the product and the review

SV and WR are parts of the names of two different versions of tesamorelin.

• What is the exact product name?
• Is it tesamorelin (EGRIFTA SV or EGRIFTA WR)?
• Who would review the tests?
• Who would answer a concern between visits?
• What would lead us to rethink the plan?

The September 2026 labels say EGRIFTA SV and EGRIFTA WR have different doses and cannot be swapped for each other.

Ask the prescriber and pharmacist to check which version your prescription names and explain its instructions.

Ask about the money and the exit terms

• What does the quoted amount include?
• What is paid separately?
• What happens to the visit fee if no medicine is prescribed?
• Is there a continuing payment or a minimum commitment?
• How do I end a plan or pause a payment?

Pick the questions that fit the conversation. Put the unanswered ones at the top of your notes.

Weighing care for deep belly fat

Use your own words to note what the answer means. Keep an unanswered question open until someone explains it.